Donoghue Forlines LLC Novavax Inc Transaction History

Donoghue Forlines LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$36.28 - $75.29 $243,076 - $504,443	-6,700 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$69.73 - $142.9 $231,573 - $474,570	3,321 Added 98.28%	6,700 $493,000
Q4 2021 Feb 11, 2022	SELL	$134.56 - $217.97 $25,835 - $41,850	-192 Reduced 5.38%	3,379 $483,000
Q3 2021 Nov 15, 2021	BUY	$177.8 - $270.58 $4,445 - $6,764	25 Added 0.71%	3,571 $740,000
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $54,208 - $115,436	448 Added 14.46%	3,546 $753,000
Q1 2021 May 14, 2021	SELL	$112.98 - $319.93 $36,944 - $104,617	-327 Reduced 9.55%	3,098 $562,000
Q4 2020 Feb 09, 2021	BUY	$78.74 - $139.5 $269,684 - $477,787	3,425 New	3,425 $382,000

291

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $674M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Donoghue Forlines LLC, based on Form 13F filings with the SEC.

Stay updated on Donoghue Forlines LLC with notifications on news.